Automatic 3-way invoice match against shipment information & rate cards, for air/ocean freight & customs brokerage/trucking operations.

To automate this highly manual process & improve the standardisation & visibility of the booking process.

About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions to treat neurological diseases in the Japanese population.

Hardware MedTech startups for neuromodulation and software startups experience in healthcare for a mobile app would be relevant.

Objectives:

To save and reduce patients with neurological diseases relating to the central nervous system, including psychiatric and neurodegenerative diseases. Solution examples include user-friendly therapeutic modalities like non-invasive neuromodulation and/or digital therapeutics at home.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).

Objective:

• To get some tools that can gather the data/visualise current stock condition and price for further ordering decision-making.

Desired Outcomes:

• Real users are from the Toyota Manufacturing plants in each country, but in using this tool, TDEM R-HQ can also utilise it.
• The primary outcome is to attain cost reduction.
• The tool should help gather data or visualise current stock conditions and prices for further ordering decision-making.

Current Limitation:

• Currently, there is no visualisation of the data and no centralised tool to do so.

About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions for the ageing population to correctly understand their own health conditions.

Startups with capabilities to develop AI algorithms based on health / vital data for chronic diseases and startups with technologies for sensing vital signals for chronic diseases would be relevant.

Objectives:

To provide an easy solution for the ageing population with chronic diseases to proactively understand their own health conditions from the patients’ homes. This includes, but should not be limited to, innovative technology to predict exacerbation before their illness gets worse.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).